Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
S-M Kim(Jeuk (South Korea)), Byoung Chul Cho(Yonsei University)
Cited by 61
Related Papers
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
|Annals of Oncology|2023|384
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
|Annals of Oncology|2013|124
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
|Clinical Cancer Research|2020|115
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
|EMBO Molecular Medicine|2019|60